COR Valuation Metrics
COR Stock Price Metrics
COR Dividend Metrics
COR Growth Rate Metrics
COR Discounted Cash Flow Metrics
| Fair Value Price | $703.78 |
| Margin of Safety | 149.86% |
COR Revenue Metrics
COR PE Ratio Metrics
| PE Ratio | 21.60 |
| PE Ratio Avg TTM | 35.53 |
| PE Ratio Avg 3Y | 30.10 |
| Current VS TTM Avg | -39.21% |
| Current VS 3Y Avg | -28.25% |
| Current VS 5Y Avg | -17.28% |
COR PS Ratio Metrics
| PS Ratio | 0.17 |
| PS Ratio Avg TTM | 0.19 |
| PS Ratio Avg 3Y | 0.17 |
| Current VS TTM Avg | -12.45% |
| Current VS 3Y Avg | -2.60% |
| Current VS 5Y Avg | +7.49% |
COR PB Ratio Metrics
| PB Ratio | 16.20 |
| PB Ratio Avg TTM | 36.55 |
| PB Ratio Avg 3Y | 68.38 |
| Current VS TTM Avg | -55.68% |
| Current VS 3Y Avg | -76.31% |
| Current VS 5Y Avg | -85.92% |
COR Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 35.32 |
| PFCF Ratio Avg TTM | 31.15 |
| PFCF Ratio Avg 3Y | 20.78 |
| Current VS TTM Avg | +13.37% |
| Current VS 3Y Avg | +69.99% |
| Current VS 5Y Avg | +97.78% |
COR Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 7.13 |
| Debt/Equity Ratio Avg TTM | 8.71 |
| Debt/Equity Ratio Avg 3Y | 10.16 |
| Current VS TTM Avg | -18.19% |
| Current VS 3Y Avg | -29.85% |
| Current VS 5Y Avg | -59.06% |
COR PEG Ratio Metrics
| PEG Ratio | 7.05 |
| PEG Ratio Avg TTM | - |
| PEG Ratio Avg 3Y | 4.19 |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | +68.39% |
| Current VS 5Y Avg | +124.34% |
COR FCF Yield
| FCF Yield | 2.83% |
| FCF Yield Avg TTM | 4.08% |
| FCF Yield Avg 3Y | 5.93% |
| Current VS TTM Avg | -30.62% |
| Current VS 3Y Avg | -52.27% |
| Current VS 5Y Avg | -57.05% |
COR Earnings Yield
| Earnings Yield | 4.63% |
| Earnings Yield Avg TTM | 2.96% |
| Earnings Yield Avg 3Y | 3.49% |
| Current VS TTM Avg | +56.43% |
| Current VS 3Y Avg | +32.56% |
| Current VS 5Y Avg | +11.31% |
COR EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 15.51 |
| Ev/Ebit Ratio Avg TTM | 18.95 |
| Ev/Ebit Ratio Avg 3Y | 18.24 |
| Current VS TTM Avg | -18.16% |
| Current VS 3Y Avg | -14.98% |
| Current VS 5Y Avg | -1.31% |
COR EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 13.05 |
| Ev/Ebitda Ratio Avg TTM | 17.44 |
| Ev/Ebitda Ratio Avg 3Y | 15.28 |
| Current VS TTM Avg | -25.19% |
| Current VS 3Y Avg | -14.60% |
| Current VS 5Y Avg | -6.07% |
COR EV/Assets Ratio Metrics
| Ev/Assets Ratio | 0.80 |
| Ev/Assets Ratio Avg TTM | 0.90 |
| Ev/Assets Ratio Avg 3Y | 0.80 |
| Current VS TTM Avg | -11.50% |
| Current VS 3Y Avg | -0.34% |
| Current VS 5Y Avg | +10.96% |
COR EV/Sales Ratio Metrics
| Ev/Sales Ratio | 0.20 |
| Ev/Sales Ratio Avg TTM | 0.21 |
| Ev/Sales Ratio Avg 3Y | 0.19 |
| Current VS TTM Avg | -6.60% |
| Current VS 3Y Avg | +6.14% |
| Current VS 5Y Avg | +15.63% |
COR Current Ratio Metrics
| Current Ratio | 0.90 |
| Current Ratio Avg TTM | 0.89 |
| Current Ratio Avg 3Y | 0.89 |
| Current VS TTM Avg | +1.12% |
| Current VS 3Y Avg | +0.84% |
| Current VS 5Y Avg | -1.64% |
COR Quick Ratio Metrics
| Quick Ratio | 0.55 |
| Quick Ratio Avg TTM | 0.54 |
| Quick Ratio Avg 3Y | 0.53 |
| Current VS TTM Avg | +1.85% |
| Current VS 3Y Avg | +3.77% |
| Current VS 5Y Avg | +0.30% |
COR ROIC Metrics
| ROIC | 13.23% |
| ROIC Avg 3Y | 14.58% |
| ROIC Avg 5Y | 13.58% |
| Current VS 3Y Avg | -9.27% |
| Current VS 5Y Avg | -2.57% |
| Current VS 10Y Avg | +12.28% |
COR Return on Assets Metrics
| ROA | 2.03 |
| ROA Avg TTM | 2.14 |
| ROA Avg 3Y | 2.52 |
| Current VS TTM Avg | -5.14% |
| Current VS 3Y Avg | -19.36% |
| Current VS 5Y Avg | +139.76% |
COR Return on Equity Metrics
| ROE | 103.06 |
| ROE Avg TTM | 168.34 |
| ROE Avg 3Y | (32.99) |
| Current VS TTM Avg | -38.78% |
| Current VS 3Y Avg | -412.40% |
| Current VS 5Y Avg | -30.61% |
COR Net Profit Margin Metrics
| Net Profit Margin | 0.48% |
| Net Profit Margin Avg TTM | 0.49% |
| Net Profit Margin Avg 3Y | 0.59% |
| Current VS TTM Avg | -3.03% |
| Current VS 3Y Avg | -18.99% |
| Current VS 5Y Avg | +121.54% |
Last Updated: Saturday, June 13, 2026
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch